Chinese 30. Chu J, Qin R, Wang NN, Wang X, Chen ML: Expression and significance of CDX2 and claudin-3 in gastric carcinoma and paracancer tissue. J Clin Exp Pathol 2011, 27:1280–5. Chinese 31. Felson DT: Bias in meta-analytic research. J Clin Epidemiol 1992, 45:885–92.PubMedCrossRef 32. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS: Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011, 17:2693–701.PubMedCrossRef 33. Ge J, Chen Z, Wu S, Chen J, Li X: Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 2009, 80:148–58.PubMedCrossRef 34. Chiaravalli AM, Klersy C, Vanoli
A, Ferretti A, Capella C: Histotype-based selleck prognostic classification of gastric Vactosertib solubility dmso cancer. World J Gastroenterol 2012, 18:896–904.PubMedCrossRef 35. Lazăr D, Tăban S, Dema A, Cornianu M, Goldiş A: Gastric cancer: the correlation between the clinicopathological factors and patients’ survival (I). Rom J Morphol Embryol 2009, 50:41–50.PubMed 36. Eda A, Osawa H, Yanaka I, et al.: Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. J Gastroenterol 2002,37(2):94–100.PubMedCrossRef
37. Mutoh H, Hayakawa H, Sakamoto H, et al.: Transgenic Cdx2 induces endogenous Cdx1 in intestinal metaplasia of Cdx2-transgenic mouse stomach. FEBS J 2009,276(20):5821–31.PubMedCrossRef 38. Almeida R, Silva E, Santos-Silva F, Silberg DG, Wang J, De Bolós C, David L: Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol 2003, 199:36–40.PubMedCrossRef 39. Mutoh H, Sakurai S, Satoh K, Tamada K, Kita H, Osawa H, Tomiyama T, Sato Y, Yamamoto H, Isoda N, Yoshida selleck screening library T, Ido K, Sugano K: Development of gastric carcinoma from intestinal metaplasia in Cdx2-transgenic mice. Cancer Res 2004, 64:7740–7.PubMedCrossRef 40. Mizoshita T, Tsukamoto T, Nakanishi H, Inada K, Ogasawara N: Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis.
J Cancer Res Clin Oncol 2003, 129:727–4.PubMedCrossRef 41. Wang XT, Xie YB, Xiao Q: siRNA targeting of Cdx2 inhibits growth of human gastric cancer MGC-803 cells. World J Gastroenterol 2012, 18:1903–1914.PubMedCrossRef 42. Huang LN, Wang DS, Chen YQ, Li W, Hu FD: Meta-analysis for cyclin E in lung cancer survival. Clin Chim Acta 2012, 413:663–668.PubMedCrossRef 43. Fan J, Wang L, Jiang GN, Gao W: Sublobectomy versus lobectomy for stage I non-small-cell lung cancer, a meta-analysis of published studies. Ann Surg Oncol 2012, 19:661–8.PubMedCrossRef 44. Christian P, Tielsch JM: Evidence for multiple micronutrient effects based on randomized controlled trials and meta-analyses in developing countries. J Nutr 2012, 142:173S-7S.PubMedCrossRef 45. Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003,56(1):1–9.PubMedCrossRef 46.